<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><title><![CDATA[Zealand leverer vægttabsdata for fedmemidlet BI 456906]]></title><description><![CDATA[<p dir="auto">Zealand leverer vægttabsdata for middel under Boehringer-samarbejde</p>
<p dir="auto">1/11 17:28</p>
<p dir="auto">Positive vægttabsdata fra et studie af Zealands lægemiddelhåb, BI 456906, offentliggøres i denne uge på årsmødet i Obesity Society i USA.</p>
<p dir="auto">Det fremgår af en meddelelse fra Zealand op til årsmødet, der løber fra den 1. til den 4. november.</p>
<p dir="auto">BI 456906 er del af Zealands samarbejde med Boehringer Ingelheim, der står for udviklingen af lægemidlet.</p>
<p dir="auto">I et fase 2-studiet har lægemiddelkandidaten vist sig at kunne give vægttab på op til 9 pct. efter 16 uger i type 2-diabetikere. Til sammenligning havde patienter på Novos GLP-1-middel Semaglutid et vægttab på 5,4 pct. i et åbent studie, hvor patienter og læger vidste, hvilket middel de fik.</p>
<p dir="auto">BI 456906 bygger på to virkningsmekanismer Glukagon og GLP-1.</p>
<p dir="auto">Tidligere i september har Boehringer også annonceret positive data for BI 456906's evne til at sænke langtidsblodsukkeret i type 2-diabetikere.</p>
<p dir="auto">På årsmødet vil Zealand i øvrigt præsentere data fra prækliniske studier af lægemiddelkandidaterne Dapiglutid, ZP8396 og ZP6590.</p>
<p dir="auto">.\˙ MarketWire</p>
]]></description><link>https://dev.proinvestor.com/forum/topic/444437/zealand-leverer-vgttabsdata-for-fedmemidlet-bi-456906</link><generator>RSS for Node</generator><lastBuildDate>Sun, 28 Jun 2026 12:25:31 GMT</lastBuildDate><atom:link href="https://dev.proinvestor.com/forum/topic/444437.rss" rel="self" type="application/rss+xml"/><pubDate>Tue, 01 Nov 2022 16:21:31 GMT</pubDate><ttl>60</ttl><item><title><![CDATA[Reply to Zealand leverer vægttabsdata for fedmemidlet BI 456906 on Fri, 04 Nov 2022 11:21:22 GMT]]></title><description><![CDATA[<p dir="auto">Godt indlæg i debatten.</p>
<p dir="auto">Samarbejder, partnerskaber eller et salg?</p>
<p dir="auto"></p><div class="card col-md-9 col-lg-6 position-relative link-preview p-0">

<div class="card-body">
<h5 class="card-title">
<a class="text-decoration-none" href="https://www.proinvestor.com/boards/107536/">
Just a moment...
</a>
</h5>
<p class="card-text line-clamp-3"></p>
</div>
<a href="https://www.proinvestor.com/boards/107536/" class="card-footer text-body-secondary small d-flex gap-2 align-items-center lh-2">



<img src="https://www.proinvestor.com/favicon.ico" alt="favicon" class="not-responsive overflow-hiddden" style="max-width:21px;max-height:21px" />



<p class="d-inline-block text-truncate mb-0"> <span class="text-secondary">(www.proinvestor.com)</span></p>
</a>
</div><p></p>
]]></description><link>https://dev.proinvestor.com/forum/post/9478430</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/9478430</guid><dc:creator><![CDATA[ProinvestorNEWS]]></dc:creator><pubDate>Fri, 04 Nov 2022 11:21:22 GMT</pubDate></item><item><title><![CDATA[Reply to Zealand leverer vægttabsdata for fedmemidlet BI 456906 on Wed, 02 Nov 2022 05:08:44 GMT]]></title><description><![CDATA[<p dir="auto">Gode ting tager tid. Det med den "tynde" pipeline er vist skudt til hjørne nu.</p>
]]></description><link>https://dev.proinvestor.com/forum/post/9478431</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/9478431</guid><dc:creator><![CDATA[HanneP]]></dc:creator><pubDate>Wed, 02 Nov 2022 05:08:44 GMT</pubDate></item><item><title><![CDATA[Reply to Zealand leverer vægttabsdata for fedmemidlet BI 456906 on Tue, 01 Nov 2022 19:12:57 GMT]]></title><description><![CDATA[<p dir="auto">Dette syntes jeg er overraskende positivt. Jeg glæder mig til at se flere detaljer omkring disse resultater.</p>
]]></description><link>https://dev.proinvestor.com/forum/post/9478429</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/9478429</guid><dc:creator><![CDATA[EliotSpitzer]]></dc:creator><pubDate>Tue, 01 Nov 2022 19:12:57 GMT</pubDate></item><item><title><![CDATA[Reply to Zealand leverer vægttabsdata for fedmemidlet BI 456906 on Tue, 01 Nov 2022 16:28:35 GMT]]></title><description><![CDATA[<p dir="auto">Zealand Pharma Announces Presentations at The Obesity Society Annual Meeting</p>
<p dir="auto"><div class="card col-md-9 col-lg-6 position-relative link-preview p-0">



<a href="https://www.globenewswire.com/news-release/2022/11/01/2545815/0/en/Zealand-Pharma-Announces-Presentations-at-The-Obesity-Society-Annual-Meeting.html" title="Zealand Pharma Announces Presentations at The Obesity Society Annual Meeting">
<img src="https://ml-eu.globenewswire.com/Resource/Download/8e5dac9c-86c4-4996-bce9-0f8ba208f970" class="card-img-top not-responsive" style="max-height: 15rem;" alt="Link Preview Image" onerror="this.parentElement.remove()" />
</a>



<div class="card-body">
<h5 class="card-title">
<a class="text-decoration-none" href="https://www.globenewswire.com/news-release/2022/11/01/2545815/0/en/Zealand-Pharma-Announces-Presentations-at-The-Obesity-Society-Annual-Meeting.html">
Zealand Pharma Announces Presentations at The Obesity Society Annual Meeting
</a>
</h5>
<p class="card-text line-clamp-3">Press release – No. 7 / 2022  Zealand Pharma Announces Presentations at The Obesity Society Annual Meeting  Results from the phase 2 clinical trial of...</p>
</div>
<a href="https://www.globenewswire.com/news-release/2022/11/01/2545815/0/en/Zealand-Pharma-Announces-Presentations-at-The-Obesity-Society-Annual-Meeting.html" class="card-footer text-body-secondary small d-flex gap-2 align-items-center lh-2">



<img src="https://www.globenewswire.com/Content/logo/favicon.ico" alt="favicon" class="not-responsive overflow-hiddden" style="max-width: 21px; max-height: 21px;" onerror="this.remove()"/>



<p class="d-inline-block text-truncate mb-0">GlobeNewswire News Room <span class="text-secondary">(www.globenewswire.com)</span></p>
</a>
</div></p>
]]></description><link>https://dev.proinvestor.com/forum/post/9478432</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/9478432</guid><dc:creator><![CDATA[ProinvestorNEWS]]></dc:creator><pubDate>Tue, 01 Nov 2022 16:28:35 GMT</pubDate></item><item><title><![CDATA[Reply to Zealand leverer vægttabsdata for fedmemidlet BI 456906 on Tue, 01 Nov 2022 16:24:46 GMT]]></title><description><![CDATA[<p dir="auto">Hør mere i dette interview om de spændende produkter inden for fedme, hvor Helge Larsen et taget ud til Zealand Pharma for at tale med CEO Adam Steensberg.</p>
<p dir="auto">Disclaimer: Zealand Pharma har betalt ir-samarbejde med <a href="http://ProInvestor.com" rel="nofollow ugc">ProInvestor.com</a>.</p>
<p dir="auto">Helge Larsen har aktier i Zealand Pharma.</p>
<p dir="auto"></p><div class="ratio ratio-16x9">
<iframe src="https://www.youtube-nocookie.com/embed/gRkHeIQMZPU" title="YouTube video player" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share; fullscreen"></iframe>
</div><p></p>
]]></description><link>https://dev.proinvestor.com/forum/post/9478424</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/9478424</guid><dc:creator><![CDATA[ProinvestorNEWS]]></dc:creator><pubDate>Tue, 01 Nov 2022 16:24:46 GMT</pubDate></item></channel></rss>